170P Anti- α gal antibodies in the context of blood group and stool and tumour-adjacent microbiome in colorectal cancer patients
ConclusionThe level of anti- α gal antibodies CRC patients is related with various metabolism influencing bacteria. Blood group antigen B is related to reduced IgM and IgG but not specific microbiome composition.Legal entity responsible for the studyCzech Ministry of Health.FundingProject AZV 16-31966A (Czech Ministry of Health).DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
152P Replicative potency of oncolytic VSV-GP differentially shapes the immune signature in three distinct syngeneic tumour models
ConclusionIn conclusion, we present a number of immune-activating consequences of virotherapy treatment in syngeneic tumour models with varying degree of virus propagation. Higher virus activity in the tumour qualitatively and quantitatively shapes the tumour microenvironment differently compared to tumours with restricted virus activity.Legal entity responsible for the studyThe authors.FundingChristian Doppler Research Association.DisclosureG. Wollmann: Advisory / Consultancy, Research grant / Funding (self): Boehringer Ingelheim. B. Spiesschaert: Full / Part-time employment: Boehringer Ingelheim. P. Erlmann: Full / Part-...
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
29P Expression profiles of serum long non-coding RNA in ovarian cancer patients receiving platinum-containing chemotherapy
ConclusionThe revealed relationships between the levels of circulating MALAT and HOTAIR in the blood plasma of patients with OC require further study of these epigenetic regulators in OC carcinogenesis and chemoresistance. Free circulating lncRNA MALAT and HOTAIR, as an element of a liquid biopsy, are potential prognostic and predictive biomarkers for OC.Legal entity responsible for the studyThe authors.FundingRFBR (project number 19-315-50012).DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
13P MDSC (myeloid-derived suppressor cells) is an important immunosuppressing factor and functionally related with VEGF and IL-17 in patients with gastrointestinal cancer
ConclusionThe key mechanisms of immunosuppression in these patients are systemic inflammation involving MDSC, VEGF and IL-17. Immune checkpoint inhibitors might be more effective with a decreased MDSC by controlling VEGF and IL-17.Legal entity responsible for the studyMasahiko Shibata.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
65P Determination of anti-pancreatic islet cell antibodies for the prevention of type 1 diabetes mellitus as an immune-related adverse event secondary to treatment with immune checkpoint inhibitors
ConclusionDetermining the level of antibodies related to diabetes prior to the treatment with immunotherapy and during the treatment may prevent immunemediated diabetes. An assessment of the positivity of antibodies at the beginning of the treatment or of seroconversion during administration (as described in the literature) may have an influence on the detection of the development of T1D.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
41P Pharmacotherapy preceding monocyte harvest interferes with the potency of monocyte-derived dendritic cell anticancer vaccine
ConclusionPharmacotherapy should be understood as concomitant factor influencing the DC vaccine product quality outcome. Certain monocyte-interfering anti-cancer pharmacotherapy combinations prior to monocyte harvest were associated with impaired quality and potency of DC-based immunotherapy.Clinical trial identificationEudraCT: 2014-003388-39.Legal entity responsible for the studyState Institute for Drug Control Czech Republic.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
140P B-cell clusters in the stroma at invasive tumour margin provide prognostic value in early-stage oral-tongue cancer patients: The discovery and validation study
ConclusionOur study highlights the prognosis of B cell-rich areas in early-stage oral-tongue cancer patients, particularly in the context of low intra-tumoral CD4 T cell densities.Legal entity responsible for the studyThe authors.FundingErasmus MC, Rotterdam, the Netherlands and HRH Princess Chulabhorn College of Medical Science, Bangkok, Thailand.DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
30P Transcriptomic landscape of tumour cells undergoing T-cell attack
ConclusionTuTACK measured the effects of an immune response rather than its activity and it represents an innovative method to identify immunologically hot tumours. Our findings suggested that TuTACK may allow better patient selection in immunotherapy clinical trials and provide hints to improve the treatment of “hot” tumours resistant to current immunotherapies.Legal entity responsible for the studyThe authors.FundingThe Danish Cancer Society (grant number R148-A9862); The Lundbeck Foundation (grant number R233-2016-3728); The Capital Region of Denmark Research Foundation (grant number R146-A5693); The National Resear...
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
106P A single dose of local IL-12 promotes anti-tumor effect of anti-EGFRvIII-CAR-T cells in a syngeneic murine model of glioblastoma
ConclusionThis study demonstrates the capacity of IL-12 as local “adjuvant” therapy to boost the efficacy of CAR T cells and to awake the endogenous anti-tumor T cell responses.Legal entity responsible for the studyUniversity of Zurich.FundingUniversity Research Priority Project and Advanced T-cell Engineered for Cancer Therapy.DisclosureM. Pule: Honoraria (self), Honoraria (institution): Autolus LTD. All other authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
171P Treatment (tx) patterns of patients with advanced renal cell carcinoma (aRCC) receiving first-line (1L) tx: Results from a cross-sectional real-world study
ConclusionASCO and NCCN guidelines recommend IO-IO combination in patients with an intermediate or high IMDC risk. However, at the time of data collection, more patients meeting these criteria received TKI monotherapy than IO-IO combination; moreover, almost a third of 1L tx aRCC patients were not even assessed. Newly introduced IO-TKI combination tx, approved during the fieldwork period, could enable clinicians to offer patients personalised tx, irrespective of risk profile.Legal entity responsible for the studyPfizer Inc.FundingPfizer Inc. (part of an alliance between Pfizer Inc. and Merck KGaA, Darmstadt, Germany).Discl...
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
82P Real-world survival with first-line (1L) chemotherapy in patients (pts) with advanced non-small cell lung cancer (aNSCLC)
ConclusionRW OS in broad histology-based populations of 1L chemo pts was similar to meta-analysis estimates from corresponding trial populations. However, RW OS in TPS-based populations, where biomarker information is more commonly available in recent cohorts, was numerically longer than in the corresponding meta-analysis trial populations. Additional analyses are planned to assess IO-chemo in RW and to determine the influence of post-progression immunotherapy and imbalances in prognostic factors on chemo treatment group outcomes.Legal entity responsible for the studyBristol-Myers Squibb.FundingBristol-Myers Squibb.Disclos...
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
14P Anti-PDL1/IL-15 fusion protein increases rare effector cells in cynomolgus monkeys and mice
ConclusionKD033 administration increases CD8+ T and NK cells, consistent with IL-15 pharmacodynamics. In addition, analysis of peripheral blood from KD033 surrogate best and non-responder mice demonstrated increases in different immune populations, which can facilitate their use as in-treatment biomarkers of KD033 activity in tumors. Importantly, KD033 administration resulted in increases in rare cytotoxic cells such as NKT and gamma delta T cells in peripheral blood which may contribute to its anti-tumor activity and immunity.Legal entity responsible for the studyKadmon Corporation LLC.FundingKadmon Corporation LLC.Disclo...
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
66P Efficacy and safety of nintedanib + docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): Updated results of the ongoing non-interventional study (NIS) VARGADO (NCT02392455)
ConclusionThis updated analysis continues to show the clinical benefit and manageable safety profile of nintedanib plus docetaxel in pts with advanced adenocarcinoma NSCLC following treatment with chemotherapy and ICIs.Clinical trial identificationNCT02392455.Legal entity responsible for the studyBoehringer Ingelheim Pharma GmbH& Co. KG.FundingBoehringer Ingelheim Pharma GmbH& Co. KG.DisclosureC. Grohe: Advisory / Consultancy: Boehringer Ingelheim. H. Mueller-Huesmann: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Roche; Honoraria (self), Advisory / Consultancy, Research grant / ...
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
125P Response assessment of metastatic uveal melanoma treated with rose bengal disodium
ConclusionImaging response assessment of pts treated with PV-10 using RECIST may lead to premature and inaccurate determination of progression. 2D-EASL provides information specific to the behavior of injected lesions. Immunotherapy-centric criteria (irRC, irRECIST and iRECIST) could be a useful alternative to 2D-EASL.Clinical trial identificationNCT00986661.Legal entity responsible for the studyProvectus Biopharmaceuticals.FundingProvectus Biopharmaceuticals.DisclosureE.A. Wachter: Full / Part-time employment: Provectus Biopharmaceuticals. All other authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
141P Identifying mechanisms of macrophage-mediated metastasis and treatment resistance in pancreatic cancer
ConclusionBlockade of these signalling molecules or their receptors disrupted the crosstalk between PDAC cells and macrophages within the TME and impaired the ability of macrophages to induce a pro-invasive phenotype to PDAC cells.Legal entity responsible for the studyThe author.FundingHas not received any funding.DisclosureThe author has declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
